First ready-to-use toxin to launch
Pharmaceutical company Galderma has confirmed the first ready-to-use liquid neuromodulator has completed its European decentralised trial in Europe.
Pharmaceutical company Galderma has confirmed the first ready-to-use liquid neuromodulator has completed its European decentralised trial in Europe.
A study presented at the American Academy of Dermatology Association Virtual Meeting Experience 2021 explained that long-term use of the human antibody tralokinumab is safe and effective in the treatment of atopic dermatitis (AD).